# A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Source: https://onco.cc/trials/nct07468851/  
OnCo record `nct07468851` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HS-10566 in bladder & urothelial cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy is a phase 1/2 interventional study registered as NCT07468851 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 180 participants planned, started 2026-08-05 and due to reach its primary completion in 2028-04-30. Interventions recorded: HS-10566.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07468851
- Phase: 1/2
- Setting: A Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07468851: https://clinicaltrials.gov/study/NCT07468851

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)

---
JSON: https://onco.cc/api/v1/entities/nct07468851.json